糖皮质激素治疗风湿病儿童的骨质疏松性骨折与椎体重塑
这项前瞻性起始队列研究纳入136例糖皮质激素治疗的风湿病儿童,6年累积椎体骨折发生率为16.3%,非椎体骨折为10.1%。63%的椎体骨折发生在治疗前2年,84%的椎体骨折儿童实现完全椎体重塑,但腰椎骨密度z评分在6年时仍低于基线。
要点
- 椎体骨折在治疗早期(前2年)高发,需早期监测。
- 多数椎体骨折儿童可实现完全椎体重塑,但部分遗留畸形。
- 疾病活动度、BMI z评分升高及早期骨密度下降预测椎体骨折。
核心结论
- 糖皮质激素治疗的风湿病儿童中椎体骨折发生早且多于非椎体骨折,84%的椎体骨折儿童完全重塑,但腰椎骨密度z评分6年时仍低。
研究设计与样本
- 前瞻性起始队列研究,由加拿大STOPP联盟领导,纳入136例糖皮质激素治疗的风湿病儿童,平均年龄9.9岁(SD 4.4)。
主要发现
- 6年累积骨折发生率:椎体骨折16.3%,非椎体骨折10.1%。
- 38例椎体骨折中24例(63%)发生在治疗前2年。
- 19例椎体骨折儿童中16例(84%)实现完全椎体重塑。
- 腰椎骨密度z评分在6个月时最低(均值-0.9,SD 1.2),6年时仍低(-0.6,SD 0.9,经身高z评分校正)。
关键数值与推荐
- 第一年疾病活动度和BMI z评分升高及前6个月腰椎骨密度z评分下降预测6年内椎体骨折。
- 较高的平均每日糖皮质激素剂量预测椎体骨折和非椎体骨折。
临床怎么用
- 对糖皮质激素治疗的风湿病儿童应早期关注椎体骨折风险,尤其是治疗前2年。
- 监测疾病活动度、BMI z评分和腰椎骨密度变化有助于识别高危患儿。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Osteoporotic fractures are an important cause of morbidity in children with glucocorticoid-treated rheumatic disorders. OBJECTIVE: This work aims to evaluate the incidence and predictors of osteoporotic fractures and potential for recovery over six years following glucocorticoid (GC) initiation in children with rheumatic disorders. METHODS: Children with GC-treated rheumatic disorders were evaluated through a prospective inception cohort study led by the Canadian STeroid-induced Osteoporosis in the Pediatric Population (STOPP) Consortium. Clinical outcomes included lumbar spine bone mineral density (LS BMD), vertebral fractures (VF), non-VF, and vertebral body reshaping. RESULTS: A total of 136 children with GC-treated rheumatic disorders were enrolled (mean age 9.9 years, SD 4.4). The 6-year cumulative fracture incidence was 16.3% for VF, and 10.1% for non-VF. GC exposure was highest in the first 6 months, and 24 of 38 VF (63%) occurred in the first 2 years. Following VF, 16 of 19 children (84%) had complete vertebral body reshaping. Increases in disease activity and body mass index z scores in the first year and declines in LS BMD z scores in the first 6 months predicted incident VF over the 6 years, while higher average daily GC doses predicted both incident VF and non-VF. LS BMD z scores were lowest at 6 months (mean -0.9, SD 1.2) and remained low by 6 years even when adjusted for height z scores (-0.6, SD 0.9). CONCLUSION: VF occurred early and were more common than non-VF in children with GC-treated rheumatic disorders. Eighty-four percent of children with VF underwent complete vertebral body reshaping, whereas vertebral deformity persisted in the remainder of children. On average, LS BMD z scores remained low at 6 years, consistent with incomplete recovery.
引用
- Ward LM, Ma J, Robinson ME, et al. Osteoporotic Fractures and Vertebral Body Reshaping in Children With Glucocorticoid-treated Rheumatic Disorders. J Clin Endocrinol Metab. 2021. PMID: 34232311. doi:10.1210/clinem/dgab494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。